{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2024-04-15T21%3A42%3A28.653Z&AnsweringBody.=Department+of+Health+and+Social+Care&uin=HL3729", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?max-ddpCreated=2024-04-15T21%3A42%3A28.653Z&AnsweringBody.=Department+of+Health+and+Social+Care&uin=HL3729", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2024-04-15T21%3A42%3A28.653Z&AnsweringBody.=Department+of+Health+and+Social+Care&uin=HL3729&_metadata=all", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&max-ddpCreated=2024-04-15T21%3A42%3A28.653Z&AnsweringBody.=Department+of+Health+and+Social+Care&uin=HL3729", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2024-04-15T21%3A42%3A28.653Z&AnsweringBody.=Department+of+Health+and+Social+Care&uin=HL3729", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?max-ddpCreated=2024-04-15T21%3A42%3A28.653Z&AnsweringBody.=Department+of+Health+and+Social+Care&uin=HL3729", "items" : [{"_about" : "http://data.parliament.uk/resources/1700671", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1700671/answer", "answerText" : {"_value" : "
We are aware that there have been supply constraints with olanzapine 210 milligram, 300 milligram, and 405 milligram powder and solvent for prolonged release suspension for injection. We worked with manufacturers to uplift production, and the issues were resolved in February 2024. We worked with NHS England to issue national communications containing advice on how to manage patients whilst there was a disruption to supply. We are not aware of any supply issues affecting oral presentations of olanzapine, or of any supply issues with any risperidone or haloperidol products.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4948", "label" : {"_value" : "Biography information for Lord Markham"} } , "answeringMemberPrinted" : {"_value" : "Lord Markham"} , "dateOfAnswer" : {"_value" : "2024-04-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL3730"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-04-22T15:15:21.697Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs: Shortages"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask His Majesty's Government what steps they are taking to mitigate the current shortage of the psychotropic medication Olanzapine, Risperidone and Haloperidol following the sudden departure of two generic manufacturers from the UK market.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1138", "label" : {"_value" : "Biography information for Lord Carlile of Berriew"} } , "tablingMemberPrinted" : [{"_value" : "Lord Carlile of Berriew"} ], "uin" : "HL3729"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }